These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 15477218

  • 1. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
    Piccaluga PP, Malagola M, Amabile M, Rondoni M, Paolini S, Pane F, Russo D, Visani G, Baccarani M, Martinelli G.
    Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
    [Abstract] [Full Text] [Related]

  • 2. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
    Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD.
    Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 6. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    J Clin Oncol; 2006 Jan 20; 24(3):460-6. PubMed ID: 16344315
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 20; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 8. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
    Pompetti F, Spadano A, Sau A, Mennucci A, Russo R, Catinella V, Franchi PG, Calabrese G, Palka G, Fioritoni G, Iacone A.
    Leuk Res; 2007 Apr 20; 31(4):563-7. PubMed ID: 16916543
    [Abstract] [Full Text] [Related]

  • 9. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P, Brune M, Andersson PO, Gustavsson B, Stockelberg D, Wadenvik H.
    Bone Marrow Transplant; 2002 Dec 20; 30(12):971-3. PubMed ID: 12476293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.
    Clin Cancer Res; 2007 Oct 15; 13(20):6136-43. PubMed ID: 17947479
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, GMALL Study Group.
    Cancer; 2007 May 15; 109(10):2068-76. PubMed ID: 17429836
    [Abstract] [Full Text] [Related]

  • 14. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 15. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T.
    J Clin Oncol; 2005 Oct 20; 23(30):7583-93. PubMed ID: 16234522
    [Abstract] [Full Text] [Related]

  • 16. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ.
    Haematologica; 2006 May 20; 91(5):663-6. PubMed ID: 16627251
    [Abstract] [Full Text] [Related]

  • 17. [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
    Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LIu, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG.
    Ter Arkh; 2005 May 20; 77(7):11-6. PubMed ID: 16116902
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
    Qin Y, Jiang B, Jiang Q, Jiang H, Li J, Zhang Y, Zhu H, Li L, Chen S, Liu Y, Huang X.
    Ann Hematol; 2009 Jan 20; 88(1):37-41. PubMed ID: 18651143
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.